Search - tctmd.com

Displaying 401 - 420 of 929

Sort: Relevancy | Date

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

TriCLASP: Tricuspid Repair With Pascal Safe, Effective at 30 days

News Conference News EuroPCR 2022

TriCLASP: Tricuspid Repair With Pascal Safe, Effective at 30 days

Yael L. Maxwell

May 19, 2022

Mystery MINOCA? Many COVID STEMIs Have No Culprit Lesion

News Conference News SCAI 2022

Mystery MINOCA? Many COVID STEMIs Have No Culprit Lesion

May 19, 2022

Evidence Grows for Conduction-System Pacing as an Alternative to CRT

News Conference News HRS 2022

Evidence Grows for Conduction-System Pacing as an Alternative to CRT

May 05, 2022

Streamlining EP Consult From the ER Pays Dividends in AF

News Conference News HRS 2022

Streamlining EP Consult From the ER Pays Dividends in AF

May 04, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

TCTMD’s Top 10 Most Popular Stories for April 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

May 02, 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

April 02, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

News Daily News

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Michael O'Riordan

March 28, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

ACC Releases Guidance on CV Issues With COVID-19

News Daily News

ACC Releases Guidance on CV Issues With COVID-19

March 16, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.